Clinical Trials Logo

Henoch-Schönlein Purpura clinical trials

View clinical trials related to Henoch-Schönlein Purpura.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05951517 Recruiting - Clinical trials for Gastrointestinal Injury

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Henoch Schönlein purpura (HSP) is the most common type of vasculitis in children, with an incidence of ~10/100,000, whereas >90% of the patients develop symptoms at <10 years of age. Although HSP is generally a self-limiting disease, it may also lead to severe complications, such as intestinal intussusception, infarction and perforation, as well as end-stage renal disease. The management of HSP includes symptomatic treatment and immunosuppressive therapy in certain patients. Previous retrospective studies have reported that most patients with gastrointestinal (GI) symptoms may benefit from early usage of glucocorticoid, whereas there are still a part of HSP patients with GI did not achieved remission after administering of steroid. Therefore, the aim of the present study was to investigate the clinical features of refractory GI HSP and the clinical outcome of mycophenolate mofetil in these patients.

NCT ID: NCT05937880 Recruiting - Clinical trials for Henoch-Schonlein Purpura

Leflunomide for Henoch-Schonlein Purpura

Lef for HSP
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This study conducted a prospective, multicenter, one-arm clinical trial on the combination of leflunomide and steroid therapy for refractory skin Henoch-Schonlein Purpura in children on the basis of ethical principles. A one-year follow-up was conducted to evaluate the changes in the main indicators (frequency of rash recurrence) and secondary indicators (proportion of kidney damage, proportion of joint involvement, T lymphocyte subpopulations, and inflammatory factors) before and after treatment, Exploring the safety and effectiveness of leflunomide in the treatment of refractory skin type HSP in children, it is expected that leflunomide combined with conventional treatment can improve the remission rate of HSP children's skin purpura and reduce HSP recurrence. The research results are expected to bring new treatment methods and strategies for this group of patients.

NCT ID: NCT03647852 Recruiting - Clinical trials for Henoch-Schönlein Purpura

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

IgA vasculitis is relatively common in children,especially in Asian countries. Abdominal manifestation could be severe, including bleeding, pancreatitis,appendicitis and intestinal intussusception. Delayed diagnosis could be fatal and cause severe complications.Nowadays no guidelines for those with severe abdominal manifestations in China.However, the most used treatment is steroid. For those severe forms are methylprednisolone pulse, IVIG, immunosuppressants and blood purification. Given the fact that different strategies lead to different endings which varies in cost, adverse effect and clinical outcomes in different medical centers, it is necessary to give birth to a useful and feasible strategy. This clinical trial is a muti-center, randomized,controlled prospective study.Patients with gastrointestinal disease will be recruited in three children's medical centres in Shanghai and will be randomized to two groups: MP group and IVIG group. Cost effect and clinical outcomes will be evaluated. Blood purification will be evaluated as a remedy when MP and IVIG fail to cure.

NCT ID: NCT02967068 Recruiting - Clinical trials for Giant Cell Arteritis

VCRC Tissue Repository

Start date: November 2016
Phase:
Study type: Observational

The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

NCT ID: NCT02939573 Recruiting - IgA Vasculitis Clinical Trials

A Randomized Multicenter Study for Isolated Skin Vasculitis

ARAMIS
Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.